HAVCR2 and non-small cell lung carcinoma: For patients with NSCLC BMs, the efficacy of other ICIs remain unknown, whose targets are T‐cell immunoglobulin‐3 (Tim‐3), OX40 (CD134), 4‐1BB (CD137), pyridine 2, 3‐dioxygenase‐1, killer cell immunoglobulin‐like receptors.